# A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy

> **NCT03400852** · PHASE2 · TERMINATED · sponsor: **Mallinckrodt ARD LLC** · enrollment: 44 (actual)

## Conditions studied

- Muscular Dystrophy, Duchenne

## Interventions

- **DRUG:** MNK-1411
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03400852
- **Lead sponsor:** Mallinckrodt ARD LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-27
- **Primary completion:** 2020-02-25
- **Final completion:** 2020-02-25
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** Slow enrollment
- **Last updated:** 2021-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03400852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03400852, "A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03400852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*